Commonwealth Equity Services, LLC Myovant Sciences Ltd. Transaction History

Commonwealth Equity Services, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 04, 2022	SELL	$11.38 - $16.4 $2,560 - $3,689	-225 Reduced 1.66%	13,353 $177,000
Q4 2021 Jan 31, 2022	SELL	$14.31 - $23.87 $7,698 - $12,842	-538 Reduced 3.81%	13,578 $211,000
Q3 2021 Oct 29, 2021	BUY	$18.94 - $26.99 $38,599 - $55,005	2,038 Added 16.87%	14,116 $316,000
Q2 2021 Aug 11, 2021	BUY	$17.07 - $24.56 $8,535 - $12,280	500 Added 4.32%	12,078 $275,000
Q1 2021 May 04, 2021	BUY	$20.46 - $25.18 $19,191 - $23,618	938 Added 8.82%	11,578 $238,000
Q4 2020 Feb 11, 2021	SELL	$13.8 - $27.62 $13,800 - $27,620	-1,000 Reduced 8.59%	10,640 $293,000
Q3 2020 Nov 05, 2020	BUY	$14.05 - $22.6 $27,257 - $43,844	1,940 Added 20.0%	11,640 $163,000
Q2 2020 Aug 12, 2020	BUY	$7.34 - $20.84 $71,198 - $202,148	9,700 New	9,700 $200,000

61.3K

Ticker MYOV
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 96,802,800
Description
Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain...

Get notified when there are updates to the investment portfolio of Commonwealth Equity Services, LLC, based on Form 13F filings with the SEC.

Stay updated on Commonwealth Equity Services, LLC with notifications on news.